e-Therapeutics plc Director/PDMR Shareholding (0163G)
24 May 2017 - 1:22AM
UK Regulatory
TIDMETX
RNS Number : 0163G
e-Therapeutics plc
23 May 2017
E-THERAPEUTICS PLC
("e-Therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY
PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Oxford, UK, 23 May 2017 - e-Therapeutics plc (AIM: ETX), the
drug discovery company, announces that it received notification on
22 May 2017 from one of its directors, Trevor Jones, that he had
purchased 59,400 shares in the Company at a price of 8.25 pence per
share. This purchase took place on 12 May 2017. His resultant
holding in the Company is now 166,897 shares representing 0.06 per
cent. of the Company's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person
closely associated
----------------------------------------------------------------------
a) Name Trevor Mervyn Jones
-------------------------- ------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------- ------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name e-Therapeutics plc
-------------------------- ------------------------------------------
b) LEI 21380049RHSSJXWKYT18
-------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence
financial instrument,
type of instrument ISIN: GB00B2823H99
Identification code
-------------------------- ------------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- ------------------------------------------
c) Price(s) and volume(s) 59,400 ordinary shares at a price of 8.25
pence per share
-------------------------- ------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ------------------------------------------
e) Date of the transaction 12 May 2017
-------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange, AIM (XLON)
-------------------------- ------------------------------------------
For further information, please contact:
e-Therapeutics plc Tel: +44 (0) 1993 883
Iain Ross, Chairman 125
Steve Medlicott, Finance Director www.etherapeutics.co.uk
Numis Securities Limited Tel: +44 (0) 207 260 1000
Michael Meade / Freddie Barnfield www.numis.com
(Corporate Finance)
James Black (Corporate Broking)
Instinctif Partners Tel: +44 (0) 207 457 2020
Melanie Toyne Sewell / Alex Shaw Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics is a drug discovery company with a unique and
proprietary in silico discovery platform. The Company is applying
its computational platform to the discovery of new drug candidates
for which it can secure robust intellectual property rights.
The therapeutic focus of the Company's discovery activity is in
areas of complex disease with unmet medical need, including
immuno-oncology. The business model is to partner these preclinical
drug candidates.
e-Therapeutics is headquartered in Oxford. For more information
about the Company please visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFLEEVIVFID
(END) Dow Jones Newswires
May 23, 2017 11:22 ET (15:22 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024